Of the six names in the Motley Fool’s “King Kong for Weight Loss” basket, Viking Therapeutics is the most direct bet on the idea that GLP-1 medicines are about to go from injections to pills. It is also the one whose entire investment case rests on clinical data that has not yet produced a dollar of revenue. Here is what Viking actually is, what its pipeline looks like, and what kind of risk profile you are really buying.
What Viking Therapeutics Is
Viking Therapeutics (VKTX) is a clinical-stage biotech, which means it has no marketed products and no meaningful revenue. Its value is entirely a bet on the future of its drug candidates. The company trades around $25 a share and has become one of the more closely followed names in the obesity race, largely because of a single asset: VK2735.
VK2735 is a dual GLP-1 and GIP receptor agonist, the same two-receptor profile as tirzepatide. What makes it stand out is that Viking is developing it in two forms at once, an injectable and an oral pill. The oral version is the part that matters for this promo, because the Fool’s secondary thesis is that the shift from shots to pills is about to redraw the market.
Why the Oral Angle Matters
The obesity market today is dominated by injections. They work, but they carry real friction: patients who dislike needles, refrigeration requirements, and weekly dosing schedules. An effective once-daily oral GLP-1 removes a large part of that friction and expands the addressable market to people who would simply never inject.
That is the opportunity Viking is chasing, and it is a genuine one. The catch is that Viking is far from the only company on that path. Novo Nordisk has an oral semaglutide, Eli Lilly has orforglipron, and the field is crowded. Viking’s oral VK2735 has generated encouraging early data, which is why the stock has moved, but “encouraging early data” is a long way from an approved, commercial product.
The Amylin Second Act
Viking has a second card in its hand: an amylin analog in development. Amylin is another hormone involved in appetite and glucose control, and combining it with a GLP-1 is one of the next frontiers the industry is exploring. If Viking’s amylin asset shows the kind of additive weight loss that would justify combining it with VK2735, it gives the company a second shot at differentiation beyond just another oral GLP-1.
That said, the amylin program is earlier-stage than VK2735, and it does not change the core reality of the stock today: Viking is a pre-revenue, binary-news machine. Its share price moves almost entirely on trial readouts, and those readouts can cut both ways.
The Risk Profile
This is the part the promo bundles over. Viking is a clinical-stage company, which is a fundamentally different risk category than Eli Lilly or even Ascendis Pharma, both of which have real, growing revenue. A disappointing trial result can send a pre-revenue biotech down sharply in a single session, and Viking has no commercial base to cushion that fall. The potential upside is large, but so is the potential downside, and position size is the whole game with a name like this.
Viking also faces competition on every front. The oral GLP-1 race includes the two largest diabetes companies in the world, and the amylin angle is being pursued by multiple competitors. Being early and interesting is not the same as being a winner. Our oral GLP-1 explainer lays out the full competitive field, and the King Kong weight loss teardown shows how Viking fits into the six-name basket.
The Bottom Line
Viking Therapeutics is a legitimate, differentiated player in the oral GLP-1 race, and VK2735 is a real asset. But this is a clinical-stage, pre-revenue company whose stock will live and die on trial data, in a field crowded with far better-capitalized competitors. Treat it as a high-variance, binary biotech bet, not as a sure thing, and size any position accordingly. For the broader biotech context, see our AI biotech stocks piece.
The Takeover Scenario
One reason pre-revenue biotechs like Viking trade the way they do is the persistent possibility of acquisition. Large pharma companies have shown they will pay enormous sums for promising obesity assets rather than build them from scratch, and a credible oral GLP-1 plus an amylin program is exactly the kind of package that attracts that attention. The takeover premium cuts both ways, though. It props up the stock on the chance of a deal, but it also means the downside is sharper if the data disappoints and the acquisition thesis evaporates. Betting on a buyout is not the same as betting on the drug, and investors should be clear about which one they are actually making. For a pre-revenue name, both outcomes, a deal at a premium or a sharp repricing on a miss, are live possibilities.
Ready to see the research? Click here to access The Motley Fool’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.